Anavex Life Sciences (AVXL) EPS (Weighted Average and Diluted) (2010 - 2025)
Anavex Life Sciences recorded quarterly EPS (Weighted Average and Diluted) of -$0.06 in Q4 2025, up 45.45% quarter-over-quarter from -$0.11 in Q3 2025, and up 57.14% year-over-year from -$0.04 in Q4 2024.
Anavex Life Sciences' EPS (Weighted Average and Diluted) history runs 13 years deep, the most recent figure standing at -$0.06 for Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) rose 57.14% year-over-year to -$0.06; the TTM figure through Dec 2025 stood at -$0.46 (up 16.36% YoY), while the FY2025 annual figure was -$0.54, down 3.85% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.06 for Q4 2025 at Anavex Life Sciences, up from -$0.11 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.06 in Q4 2025 to a low of -$0.19 in Q3 2022.
- A 5-year average of -$0.14 and a median of -$0.14 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) decreased 27.27% in 2024 and surged 57.14% in 2025, its largest moves.
- Anavex Life Sciences' EPS (Weighted Average and Diluted) stood at -$0.17 in 2021, then increased by 0.91% to -$0.17 in 2022, then surged by 33.88% to -$0.11 in 2023, then dropped by 27.27% to -$0.14 in 2024, then soared by 57.14% to -$0.06 in 2025.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.06, -$0.11, and -$0.16 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | -0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.06 |
| Sep 30, 2025 | -0.11 |
| Jun 30, 2025 | -0.16 |
| Mar 31, 2025 | -0.13 |
| Dec 31, 2024 | -0.14 |
| Sep 30, 2024 | -0.14 |
| Jun 30, 2024 | -0.14 |
| Mar 31, 2024 | -0.13 |
| Dec 31, 2023 | -0.11 |
| Sep 30, 2023 | -0.13 |
| Jun 30, 2023 | -0.14 |
| Mar 31, 2023 | -0.17 |
| Dec 31, 2022 | -0.17 |
| Sep 30, 2022 | -0.19 |
| Sep 30, 2021 | -0.17 |
| Mar 31, 2017 | -0.04 |
| Dec 31, 2016 | -0.08 |
| Sep 30, 2016 | -0.18 |
| Jun 30, 2016 | -0.06 |
| Mar 31, 2016 | -0.06 |
| Dec 31, 2015 | -0.12 |
| Sep 30, 2015 | -0.21 |
| Jun 30, 2015 | -0.22 |
| Mar 31, 2015 | -0.12 |
| Dec 31, 2014 | -0.06 |
| Sep 30, 2014 | -0.98 |
| Jun 30, 2014 | -0.03 |
| Mar 31, 2014 | -0.03 |
| Dec 31, 2013 | -0.01 |
| Sep 30, 2013 | -0.10 |
| Jun 30, 2013 | -0.01 |
| Dec 31, 2012 | -0.01 |
| Sep 30, 2012 | -0.01 |
| Jun 30, 2012 | -0.16 |
| Mar 31, 2012 | -0.03 |
| Dec 31, 2011 | -0.08 |
| Sep 30, 2011 | -0.05 |
| Jun 30, 2011 | -0.06 |
| Mar 31, 2011 | -0.08 |
| Dec 31, 2010 | -0.08 |
| Sep 30, 2010 | -0.13 |